Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001193125-25-238370·Longitude Capital Partners IV, LLC
Schedule 13D ownership disclosure
Zenas Biopharma Inc
Common Stock, $0.0001 par value per share · CUSIP: 98937L105
Event date: 2025-10-09
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Longitude Capital Partners IV, LLCReported CIK 0001829169
Shares: 1,832,669 · Class: 3.4%
- Longitude Venture Partners IV, L.P.Reported CIK 0001787456
Shares: 1,832,669 · Class: 3.4%
- Longitude Prime Partners, LLCReported CIK 0001865779
Shares: 774,530 · Class: 1.4%
- Longitude Prime Fund, L.P.Reported CIK 0001865844
Shares: 774,530 · Class: 1.4%
- Patrick G. EnrightReported CIK 0001253886
Shares: 2,631,522 · Class: 4.9%
- Juliet Tammenoms BakkerReported CIK 0001431159
Shares: 2,607,199 · Class: 4.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-238370
- Form type
- SCHEDULE 13D/A
- Filer
- Longitude Capital Partners IV, LLC
- CIK
- CIK 1829169
- Filed
- Oct 14, 2025
- Reporting period
- Oct 09, 2025
- Description
- Schedule 13D beneficial ownership